Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora Therapeutics Inc. is based in WATERTOWN, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-243.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -98.95% |
| Return on Assets (Trailing 12 Months) | -87.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 10.54 |
| Quick Ratio (Most Recent Fiscal Quarter) | 10.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.11 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.13 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.33 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.53 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.57 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 161.95M |
| Free Float | 118.54M |
| Market Capitalization | $285.02M |
| Average Volume (Last 20 Days) | 0.73M |
| Beta (Past 60 Months) | 2.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 26.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 47.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |